Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial

NCT06850090 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

210

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer
Rectal Cancer Patients

Interventions

COMBINATION_PRODUCT: TAS-102
COMBINATION_PRODUCT: Capecitabine

Sponsor

Shandong Cancer Hospital and Institute